| Code | CSB-RA024405MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to VGL-101, targeting TREM2 (Triggering Receptor Expressed on Myeloid cells 2), a critical immunomodulatory receptor predominantly expressed on microglia, macrophages, and dendritic cells. TREM2 plays an essential role in regulating innate immune responses, phagocytosis, and inflammatory signaling within the central nervous system and peripheral tissues. This receptor functions by recognizing lipids and lipoproteins, triggering downstream signaling pathways that promote microglial survival, proliferation, and debris clearance. Dysregulation of TREM2 has been strongly implicated in neurodegenerative diseases, particularly Alzheimer's disease, where loss-of-function mutations significantly increase disease risk, as well as in Nasu-Hakola disease and frontotemporal dementia.
VGL-101 represents a therapeutic antibody candidate designed to modulate TREM2 activity and enhance microglial function. This biosimilar antibody serves as a valuable research tool for investigating TREM2-mediated immune responses, exploring microglial biology, and studying neuroinflammatory mechanisms underlying neurodegenerative disorders. It enables researchers to examine receptor activation, ligand interactions, and downstream signaling cascades in various experimental models.
There are currently no reviews for this product.